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SUMMARY
B cell chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia that follows an extremely variable 
clinical course. Several important prognostic parameters defining pathogenic and clinical subgroups of CLL have been 
identified and validated recently. The biological significance of immunoglobulin (Ig) heavy chain variable region gene 
(IgHV) mutational status and associated ZAP-70 over-expression, CD38 and chromosomal aberrations have enabled to 
identify patients at high risk for early disease progression and inferior survival. Moreover, studies of the B cell antigen 
receptor (BCR) structure and receptor signalling have been most helpful in revealing some new aspects of the biology 
of this disease. In particular, the analysis of IG genes has revealed that the expressed IgHV/IgKV/IgLV gene repertoires of 
CLL cells differ from those of normal B cells. A further unique feature of the CLL IG repertoire is the existence of subsets 
of cases with “stereotyped” BCRs. Accumulating molecular and phenotypic data support the notion that CLL develop-
ment and evolution is not a simple scholastic event and strongly indicates a role for antigen in driving the cell of origin 
for at least some subsets of CLL cases.
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INTRODUCTION
B cell chronic lymphocytic leukaemia (CLL) is the 
most common adult leukaemia in Western countries. It 
is characterized by a progressive, monoclonal accumula-
tion of small neoplastic B cells in the blood, bone mar-
row and lymphoid tissues. Most CLL cells express CD5, 
CD23, and low levels of surface immunoglobulin (Ig) [1, 
2]. CLL follows an extremely variable clinical course with 
overall survival times ranging from months to decades [1, 
2]. Recently, several important observations [3-9] related 
to the biological significance of immunoglobulin heavy 
chain variable region gene (IGHV) mutational status and 
associated ZAP-70 over-expression, CD38, and chromo-
somal aberrations have enabled identification of patients at 
high risk for early disease progression and inferior survival. 
Furthermore, studies of the structure and function of the B 
cell antigen receptor (BCR) used by these leukaemic cells 
have helped define the biology of this disease [10-12].
IMMUNOGLOBULIN DIVERSITY
The extraordinary capacity of the human immune sys-
tem to cope with an immense variety of antigenic stimuli 
is attributed to the activity of three processes which alter 
the genomic sequence and structure at Ig loci of B cells: 
(1) somatic recombination; (2) somatic hypermutation 
(SHM); and, (3) class switch recombination (CSR) [13].
IGHV-IGHD-IGHJ recombination
The variable regions of both heavy and light chains 
contain three hypervariable areas (complementation 
determining regions, CDRs: CDR1, CDR2, CDR3) and 
four relatively invariant framework areas (FRs: FR1, FR2, 
FR3, FR4) [13]. At the genomic level, immunoglobulin 
variable region is encoded by separate genes that become 
joined together by the process called somatic recombi-
nation to make a functional gene [14]. In heavy chain 
genes, there are three distinct genes encoding for parts 
of the variable region: variable (V), diversity (D) and 
joining (J) genes [15]. Light chain variable regions com-
prise only two genes, V and J [16, 17]. Genes that can 
be recombined have specific sequence motifs adjacent 
to them, called recombination signal sequences, or RSS 
motifs [18, 19].
Somatic recombination takes place at the early stages 
of B cell differentiation within the bone marrow. Ig gene 
rearrangements usually start at the heavy chain locus 
(IgH) followed by similar rearrangements at the Ig light 
chain loci, first at the kappa locus (IgK) and, if failed, 
at the lambda locus (IgL) [20]. B cells which have com-
pleted functional recombination of both heavy and light 
chain variable region genes express IgM on the surface 
and migrate to secondary lymphoid organs. Cell surface 
expression of functional Ig molecules is necessary for the 
continued survival of early B cells.
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Somatic hypermutation
Somatic hypermutation (SHM) of Ig variable genes 
forms a second cycle of diversification after somatic 
recombination which increases antibody diversity and 
produces antibodies with higher specificity [21]. During 
this process, mainly base substitutions and occasionally 
insertions/deletions are introduced into a region of 1-2 
kb surrounding the antibody-coding sequence. In nor-
mal B cells, replacement mutations are preferentially clus-
tered within the CDRs rather than the FRs. The current 
model for SHM describes the process as being divided 
into two phases: the first activation-induced deaminase 
(AID)-dependent phase creating substitutions at C•G 
pairs and the second phase creating substitutions at A•T 
pairs [22-25].
The SHM is classically considered to occur within the 
germinal centre following encounter with antigen. Cells 
expressing high affinity antibody molecules are positively 
selected and differentiate into either memory B cells or 
plasma cells [21, 22, 26]. Once selected, memory B cells 
no longer require surface immunoglobulin or antigen for 
continued long term survival. Mutated cells that produce 
low affinity antibody or fail to produce antibody, like the 
equivalent B cell precursors in the bone marrow, undergo 
apoptosis within the germinal centre. The consequence 
of the SHM is the selection of B cells that produce high 
affinity antibodies.
Germinal centres (GCs) have long been considered as 
the only sites capable of sustaining a high rate of somatic 
hypermutation [26]. Contrary to this idea, it has recently 
been found that splenic autoreactive B cells in autoim-
mune  MRL/Faslpr  mice  proliferated  and  underwent 
active somatic hypermutation at the T zone–red pulp bor-
der rather than in GCs [27]. These results implicate this 
region as an important site for hypermutation. Because 
somatic mutations can create autoreactive B cells from the 
innocuous ones [28], mechanisms that censor autoreactive 
mutants are likely to be important in the GC. These protec-
tive mechanisms may be the reason why mutation is nor-
mally restricted to the GC. However, when the antigenic 
stimulus is chronic and the antigens involved may stim-
ulate through unique pathways, B cells may mutate else-
where and thereby escape the mechanisms that normally 
censor autoreactive B cells in the GC environment.
Class switch recombination
The IgH locus consists of an ordered array of five con-
stant region (IgHC) genes: mu, delta, gamma, epsilon and 
alpha. Class switch recombination (CSR) replaces the 
IgHC gene to be expressed from mu to gamma or epsilon 
or alpha, resulting in switching of antibody isotype from 
IgM to IgG, IgE, or IgA, respectively, without changing 
antigen specificity. Each isotype determines the manner 
in which captured antigens are eliminated or the location 
where the IG is delivered and accumulated [13, 29].
CSR is induced in vivo by both T-dependent (TD) 
and T-independent (TI) antigens [30]. B-cell activation 
by TD antigens requires interaction of the CD40 ligand 
expressed on activated T cells and CD40 on the surface 
of B cells. T-independent antigens can activate B cells in 
the absence of direct T- and B-cell interactions. Recent 
studies have shown that is possible to mimic in vitro TD 
antigen stimulation by culturing B cells in the presence 
of anti-CD40 along with specific cytokines, and TI acti-
vation by treatment with LPS plus or minus the addition 
of specific cytokines. In concert with antigen-dependent 
activation, cytokine-induced signalling provides speci-
ficity to CSR [31].
CLL SUBGROUPS: CLINICAL IMPLICATIONS
One of the most important molecular genetic param-
eters defining pathogenic and prognostic subgroups of 
CLL is the mutational status of the IGHV genes [1, 3, 4, 
8, 32-35]. Other surrogate markers such as ZAP-70 and 
CD38 have also been identified and validated [3, 8, 9, 36, 
37]. Moreover, genomic aberrations, telomere length and 
BCR signalling have been shown to be of pathogenic and 
clinical relevance in CLL [1, 2, 5, 8, 38].
Mutational status of immunoglobulin  
genes and surrogate markers in CLL
CLL cells are CD5+ cells and express IgM/IgD [1, 10, 
11]. This phenotype could be reported as a mantle zone-
like phenotype of naive cells, which express unmutated Ig 
genes. In this concept, CLL was initially thought to carry 
little, if any, somatic mutation. This idea was modified 
in 1999 when two groups of investigators demonstrated 
a strong correlation between mutational status and dis-
ease prognosis [3, 4].The analysis of IgHV gene muta-
tions revealed two distinct categories of CLL, with and 
without somatic mutations. In these studies IgHV gene 
sequences with differences of > 2% from the most similar 
germline gene were considered as “mutated” to avoid the 
possibility that some of these differences might represent 
unknown allelic polymorphisms in the IGH locus [34]. 
IgHV sequences that exhibited <2% difference from the 
germline gene were considered as “unmutated”.
Somatic mutations do not appear to occur uniformly 
among IgHV gene subgroups, rather they display a hier-
archy of mutations (IgHV3> IgHV4> IgHV1) [6, 39]. 
Differences appear even more striking when consider-
ing individual IgHV genes, with IgHV1-69 carrying very 
few mutations as opposed to IgHV3-07, IgHV3-23 and 
IgHV4-34, which show a high load of mutations. These 
differences may indicate that the CLL precursors received 
contrasting stimulations by distinct types of antigen prior 
to leukaemic transformation or that the precursors were 
transformed into leukaemic cells at distinct maturation 
stages [1, 10, 11].  321
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CD38 is a membrane protein that marks cellular acti-
vation and maturation and has signalling activity [8, 
32, 36]. CD38 expression is associated with neoplastic 
cells showing atypical morphology, diffuse bone marrow 
infiltration, high peripheral blood lymphocytosis and a 
less favourable overall prognosis. Further studies have 
revealed that CD38 and IgHV mutation status often over-
lap, although not always, but CD38 may perhaps vary over 
time [40]. CD38 is now viewed as an independent prog-
nostic marker of outcome, with its own biological and 
clinical value [36, 41].
In a pioneering gene-expression profiling study in CLL, 
a panel of genes has been identified in which the expres-
sion of a small subgroup of genes, including those encoding 
ZAP-70, IM1286077, and C-type lectin, correlated with the 
mutational status of IgVH genes [42]. ZAP-70 (zeta-asso-
ciated protein 70) is a receptor-associated protein tyrosine 
kinase originally found in T cells. Recent data have shown 
that the expression of ZAP-70 protein is strongly associated 
with CLL cells carrying unmutated IgVH genes [9, 37]. 
The immunofluorescence method for identifying ZAP-70+ 
cells in CLL is not fully standardized amongst different lab-
oratories, and it remains to be determined whether this 
parameter is amenable to the routine clinical workup of 
patients with CLL. Therefore, knowing both ZAP-70 level 
and IgHV mutational status provides more useful prognos-
tic information than knowing only one.
Biases in V gene use and Stereotyped BCRs
The expressed IgHV/IgKV/IgLV gene repertoires of 
CLL cells differ from those of normal B cells [1, 6, 7, 10, 
11, 39]. CLL cells use predominantly IgHV1, IgHV3 and 
IgHV4 subgroup genes in a distribution that is different 
from that reported for normal peripheral blood CD5+ 
B lymphocytes [6, 39]. Specifically, the IgHV1 family is 
overexpressed and the IgHV3 subgroup is underexpressed 
in relation to the circulating CD5+ repertoire.
The mature normal Ig repertoire is dominated by few 
genes without evidence for preferential pairings of Ig 
heavy/light chain genes or subgroups [43, 44]. No asso-
ciations exist between heavy/light chain CDR3 lengths 
and sequences or between IGHV/IGHD/IGHJ genes 
[45]. In contrast, as recently shown by several groups, 
a unique feature of the CLL IG repertoire is the exis-
tence of subsets of cases with “stereotyped” BCRs [1, 6, 
7, 46-55]. Along these lines, we have recently demon-
strated that stereotyped HCDR3 sequences may be iden-
tified in >20% of CLL cases [55]. Importantly, the com-
parison of CLL sequences to non-CLL sequences from B 
cells of diverse sources has revealed that HCDR3 restric-
tion is “CLL-biased” [55]. Considering the extremely low 
probability (10-12) of co-expression of identical BCRs, the 
aforementioned findings further support the notion that 
CLL development and evolution is not a simple scholastic 
event and indicates a role for antigen in driving the cell of 
origin for at least some subsets of CLL cases.
BCR signalling
The preceding molecular and phenotypic data suggest 
that antigenic stimulation of the CLL precursor cells is 
likely to have occurred prior to or during leukaemic trans-
formation [1, 10, 11]. However, it is also possible that anti-
genic stimulation exerts a promoting effect on the growth 
of certain CLL clones following leukaemic transformation 
[1, 10, 11]. This is supported by evidence that a number of 
CLL cases have an intact BCR-initiated signal transduc-
tion pathway. These cases are particularly frequent among 
the unmutated and CD38+ B-CLL subgroups [56]. It has 
been shown that the majority of unmutated (UM) CLL 
cases are able to signal via sIgM. In contrast, the major-
ity of mutated (M) CLL cases fail to signal via sIgM in 
vitro. Approximatelly 50% of M-CLL cases unable to sig-
nal via sIgM were able to signal via sIgD [1, 11, 3]. A fur-
ther smaller subset was competent to signal only via Ig-α 
[57]. The ability to signal via other molecules in the BCR 
indicates that downstream signal transduction pathways 
are operative in CLL. Therefore, failure to signal is a mem-
brane-proximal event characteristic of anergic cells. The 
distinctive anergic status in the majority of M-CLL, and in 
proportion of UM-CLL, is more likely the result of prior 
signalling events, which have rendered the cell membrane 
resistant to further stimulation.
CONCLUSION
A large body of evidence suggests that CLL develop-
ment and evolution is not a simple scholastic event and 
indicates a role for antigen in driving the cell of origin for 
at least a proportion of CLL cases. It would not be unrea-
sonable to speculate that stimulation through the BCR 
may occur at different time-points in the natural history 
of the disease, depending upon the nature of the anti-
genic element(s). The message is clear: let´s try to find 
the antigens.
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KRATAK SADRŽAJ
H r o  n i č  n a   l i m  f o  c i t  n a   l e  u  k e  m i  j a   k o  j a   p o  t i  č e   o d   B ‑ ć e ‑
l i  j a  ( B ‑H L L )  j e  n a j č e  š ć i  o b  l i k  l e  u  k e  m i  j e  k o d  o d  r a  s l i h  o s o ‑
b a .   O n a   s e   o d  l i  k u  j e   i z  u  z e t  n o   p r o  m e n  q i  v i m   k l i  n i č  k i m   t o ‑
k o m .  N e  d a v  n o  j e  u t v r  đ e  n o  n e  k o  l i  k o  p a  t o  l o  š k i h  i  k l i  n i č  k i h  
p a  r a  m e  t a  r a   B ‑H L L   v a  ž n i h   z a   p r o g  n o  z u   o v e   b o  l e  s t i .   P r i  k a ‑
z a n   j e   p r e  g l e d   s a  v r e  m e  n i h   p r i  s t u  p a   k l i  n i č  k o ‑ p a  t o  l o  š k o j  
p r o g  n o  z i   t o  k a   B ‑H L L ,   k a o   i   r e  z u l  t a  t i   s a  v r e  m e  n i h   m o  l e  k u ‑
l a r  n o  g e  n e t  s k i h   a n a  l i  z a   o v o g   o b o  q e  w a .   O t  k r i  v e  n a   s u   n o ‑
v a   s a  z n a  w a   o   b i  o  l o  š k o m   z n a č e  wu   m u  t a  c i  o  n o g   s t a  t u  s a   g e  n a  
p r o  m e n  q i  v o g  r e  g i  o  n a  t e  š k i h  l a  n a  c a  ( IgHV)  i m u  n o  g l o  b u  l i ‑
na (Ig) ,   k a o   i   z n a č a j   p o  v e  z a  n o  s t i   s   p r e  k o  m e r  n o m   e k s  p r e  s i ‑
jom ZAP­70,  e k s  p r e  s i  j o m  CD38 i  a b e  r a  c i  j a  m a  h r o  m o  z o  m a ,  k o ‑
j a   o m o  g u  ć a  v a  j u   p r e  p o  z n a  v a  w e   b o  l e  s n i  k a   k o d   k o  j i h   p o  s t o  j i  
v i  s o k   r i  z i k   z a   r a  n i   r a z  v o j   b o  l e  s t i   i   k r a  ć e   p r e  ž i  v q a  v a ‑
w e .   I s t r a ž i v a w a   k o  j a   s u   p r o  u  č a  v a  l a   s t r u k  t u  r u   r e  c e p  t o  r a  
a n  t i  g e  n a   B ‑ ć e  l i  j a   ( BCR)   i   n a č i n   p r e  n o  š e  w a   r e  g u  l a  t o r  n i h  
s i g  n a  l a   p o  m o  g l a   s u   u   o t  k r i  v a  wu   n o  v i h   b i  o  l o  š k i h   a s p e  k a ‑
t a   b o  l e  s t i .   D e  t a q  n a   a n a  l i  z a   Ig  p o  k a  z a  l a   j e   d a   s e   r e  p e r  t o  a r  
m a  n i  f e  s t o  v a  n i h  IgHV/IgKV/IgLV ge  na kod B‑HLL raz  li  ku  je od 
r e  p e r  t o  a  r a   n o r  m a l  n i h   B ‑ l i m  f o  c i  t a .   D o  d a t  n a   j e  d i n  s t v e  n a  
o d  l i  k a   i m u  n o  g l o  b u  l i n  s k o g   r e  p e r  t o  a  r a   B ‑H L L   j e   p o  s t o  j a  w e  
p o d  g r u  p a  s t e  r e  o  t i p  n i h  r e  c e p  t o  r a .  Re  z u l  t a  t i  i s  t r a  ž i  v a  w a  
m o  l e  k u  l a r  n i h   i   f e  n o  t i p  s k i h   o d  l i  k a   o v e   b o  l e  s t i   p o  d r  ž a ‑
va  ju stav da na  sta  nak i raz  voj B‑HLL ni  je is  kqu  či  vo po  sle‑
d i  c a   j e d  n o  s t a v  n o g   s t o  h a  s t i č  k o g   d o  g a  đ a  w a ,   v e ć   n a  g l a  š a  v a  j u  
i   v a  ž n u   p o d  s t i  c a j  n u   u l o  g u   a n  t i  g e  n a   u   p r e d  o  d r e  đ i  v a  wu   m a ‑
tič  ne klo  no  ge  ne će  li  je ko  ja po  ti  če od bo  le  sti bar kod ne‑
kih pod  gru  pa bo  le  sni  ka sa B‑HLL.
Kqučne reči: hronična limfocitna leukemija; kliničke 
odlike; molekularna genetika; imunoglobulinski reper‑
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